Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Oral Oncol. 2021 Oct;121:105511. doi: 10.1016/j.oraloncology.2021.105511. Epub 2021 Aug 30.
To evaluate the oncological, functional and voice rehabilitation outcomes of transoral robotic surgery for total laryngectomy (TORS-TL).
A retrospective chart review of patients treated by TORS-TL was conducted at a single academic medical center. The following outcomes were studied: indication; average robotic set-up and operative times; mean estimated blood loss; postoperative complications; re-feeding features; mean hospital stay; need of adjuvant therapy and voice rehabilitation type.
TORS-TL was performed in 10 patients for the following indications: nonfunctional larynx (N = 2); low-grade cricoid chondrosarcoma (N = 3) and recurrent laryngeal cancer after (chemo) radiation (N = 5). Two patients were excluded because the larynx was not exposable. Average robotic set-up and operative times were 20 and 278 min, respectively. The mean estimated blood loss was 50 mL. The mean hospital stay was 13.9 days (8-28 days). There was no local recurrence in patients operated for cancer recurrence (N = 5) 5 years after the surgery. Distant metastases occurred in one patient. A patient with laryngeal chondrosarcoma experienced local failure 3 years after TORS-TL. The voice rehabilitation consisted of esophageal voice (N = 2) and tracheoesophageal prosthesis (Provox®, N = 8). The main reasons for prosthesis replacement were transprosthetic (79%) and periprosthetic leaks (21%). The median lifespan of prostheses was 81 days.
TORS-TL may be a safe and effective surgical approach for selected surgical indications. Future controlled studies are needed to determine additional indications and limitations of this procedure.
评估经口机器人手术(TORS-TL)行全喉切除术的肿瘤学、功能和嗓音康复效果。
在一家学术医学中心对接受 TORS-TL 治疗的患者进行了回顾性图表审查。研究了以下结果:适应证;平均机器人设置和手术时间;平均估计失血量;术后并发症;再喂养特征;平均住院时间;辅助治疗的需要和嗓音康复类型。
TORS-TL 用于以下适应证的 10 例患者:无功能喉(N=2);低级别环状软骨软骨肉瘤(N=3)和放射治疗(化疗)后复发性喉癌(N=5)。由于喉无法暴露,有 2 例患者被排除在外。平均机器人设置和手术时间分别为 20 分钟和 278 分钟。平均估计失血量为 50 毫升。平均住院时间为 13.9 天(8-28 天)。在因癌症复发而接受手术的 5 例患者中,无局部复发(N=5)。远处转移发生在 1 例患者中。1 例患有喉软骨肉瘤的患者在 TORS-TL 后 3 年发生局部失败。嗓音康复包括食管嗓音(N=2)和气管食管假体(Provox®,N=8)。更换假体的主要原因是假体穿孔(79%)和假体周围渗漏(21%)。假体的中位寿命为 81 天。
TORS-TL 可能是一种安全有效的手术方法,适用于选定的手术适应证。未来需要进行对照研究,以确定该手术的其他适应证和局限性。